manejo del paciente con dispepsia - Instituto Guatemalteco de ...
manejo del paciente con dispepsia - Instituto Guatemalteco de ... manejo del paciente con dispepsia - Instituto Guatemalteco de ...
202. Delaney B, Moayyedi P, Forman D. Helicobacter pylori infection. Clin Evid 2002;7: 414-428.203. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pyloriinfection. Ad Hoc Committee on Practice Parameters of the American College ofGastroenterology. Am J Gastroenterol 1998; 93: 2.330-2.338.204. Gisbert JP, Calvet X, Gomollón F, Sainz R. Conferencia de consenso.Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la ConferenciaEspañola de Consenso. Med Clin (Barc) 2000; 114: 185-195.205. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P.A meta-analysis comparing eradication, healing and relapse rates in patients withHelicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther2001; 15: 1.949-1.958.206. Gisbert JP, Boixeda D, de Argila CM, Bermejo F, Redondo C, de Rafael L.Erosive duodenitis: prevalence of Helicobacter pylori infection and response toeradication therapy with omeprazole plus two antibiotics. Eur J Gastroenterol Hepatol1997; 9: 957-962.207. Shiotani A, Nishioka S, Iguchi M, Yanaoka K, Okada K, Tamai H et al. Duodenalerosions after eradication of Helicobacter pylori infection. Gastrointest Endosc 2001;54: 448-453.208. Laine L, Cohen H, Sloane R, Marin-Sorensen M, Weinstein WM. Interobserveragreement and predictive value of endoscopic findings for H. pylori and gastritis innormal volunteers. Gastrointest Endosc 1995; 42: 420-423.209. Vincze A, Karadi O, Hunyady B, Pakodi F, Suto G, Mozsik G. One year follow-upof patients after successful Helicobacter pylori eradication therapy. J Physiol Paris2001; 95: 457-460.210. Lehmann FS, Renner EL, Meyer-Wyss B, Wilder-Smith CH, Mazzucchelli L,Ruchti C et al. Helicobacter pylori and gastric erosions. Results of a prevalence studyin asymptomatic volunteers. Digestion 2000; 62: 82-86.211. Kate V, Ananthakrishnan N, Badrinath S, Amarnath SK, Balamurugan M,Ratnakar C. Helicobacter pylori infection and erosive gastritis. J Assoc PhysiciansIndia 1998; 46: 436-437.212. Taha AS, Sturrock RD, Russell RI. Mucosal erosions in longterm non-steroidalanti-inflammatory drug users: predisposition to ulceration and relation to Helicobacterpylori. Gut 1995; 36: 334-336.213. Annibale B, Marignani M, Monarca B, Antonelli G, Marcheggiano A, Martino G etal. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patientswith asymptomatic gastritis. Ann Intern Med 1999; 131: 668-672.214. Veldhuyzen van Zanten SJ, Sherman PM. Helicobacter pylori infection as acause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: asystematic overview. CMAJ 1994; 150: 177-185.215. McColl KE. The role of Helicobacter pylori eradication in the management ofacute bleeding peptic ulcer. Eur J Gastroenterol Hepatol 1995; 7: 753-755.101
216. Sharma VK, Sahai AV, Corder FA, Howden CW. Helicobacter pylori eradicationis superior to ulcer healing with or without maintenance therapy to prevent furtherulcer haemorrhage. Aliment Pharmacol Ther 2001; 15: 1.939-1.947.217. Buring SM, Winner LH, Hatton RC, Doering PL. Discontinuation rates ofHelicobacter pylori treatment regimens: a meta-analysis. Pharmacotherapy 1999; 19:324-332.218. Penston JG, McColl KE. Eradication of Helicobacter pylori: an objectiveassessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-243.219. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation oftreatment regimens to cure Helicobacter pylori infection - a meta-analysis. AlimentPharmacol Ther 1999; 13: 857-864.220. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O´Morain Cet al. Eradication of Helicobacter pylori using one-week triple therapies combiningomeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1: 138-144.221. Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S et al. Impact ofrabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pyloriinfection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther1999; 13: 741-746.222. Wong BC, Wong WM, Yee YK, Hung WK, Yip AW, Szeto ML et al. Rabeprazolebased3- day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy forthe treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15:1.959-1.965.223. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M et al. Eradicationrates of clarithromycin-resistant Helicobacter pylori using either rabeprazole orlansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002; 16:1.933-1.938.224. Veldhuyzen Van Zanten S, Lauritsen K, Delchier JC, Labenz J, De Argila CM,Lind T et al. One-week triple therapy with esomeprazole provides effective eradicationof Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14:1.605-1.611.225. Tulassay Z, Kryszewski A, Dite P, Kleczkowski D, Rudzinski J, Bartuzi Z et al.One week of treatment with esomeprazole-based triple therapy eradicatesHelicobacter pylori and heals patients with duodenal ulcer disease. Eur JGastroenterol Hepatol 2001; 13: 1.457-1.465.226. Laine L. Esomeprazole in the treatment of Helicobacter pylori. Aliment PharmacolTher 2002; 16 (Supl. 4): 115-118.227. Schmid CH, Whiting G, Cory D, Ross SD, Chalmers TC. Omeprazole plusantibiotics in the eradication of Helicobacter pylori infection: a meta-regressionanalysis of randomized, controlled trials. Am J Ther 1999; 6: 25-36.102
- Page 60 and 61: En la úlcera gástrica2.12.7. ÚLC
- Page 62 and 63: 2.12.9.11. Si una vez finalizado el
- Page 64 and 65: Algoritmo 4. Paciente con úlcera d
- Page 66 and 67: 3 INFORMACIÓN PARA EL USO RACIONAL
- Page 68 and 69: Subgrupo Efectos Adversos Contraind
- Page 70 and 71: Subgrupo Efectos adversos Contraind
- Page 72 and 73: 4 AnexosIDESCRIPCIÓN DE LA REVISI
- Page 74 and 75: Valor diagnóstico de la dispepsia.
- Page 76 and 77: IINIVELES DE EVIDENCIA Y GRADOS DE
- Page 78 and 79: Estudios de historia natural y pron
- Page 80 and 81: DiagnósticoGrado derecomendaciónA
- Page 82 and 83: IIIDEFINICIONES DE ENTIDADES Y TÉR
- Page 84 and 85: IVPRUEBAS PARA LA DETECCIÓN DEL HE
- Page 86 and 87: VSIGNIFICADO CLÍNICO DE LOS HALLAZ
- Page 88 and 89: VIFACTORES FACILITADORES Y BARRERAS
- Page 90 and 91: VIIIINFORMACIÓN PARA PACIENTES¿QU
- Page 92 and 93: ¿QUÉ TRATAMIENTO HE DE REALIZAR?E
- Page 94 and 95: XDIRECCIONES DE INTERÉS EN INTERNE
- Page 96 and 97: XI REFERENCIAS BIBLIOGRÁFICAS© Ma
- Page 98 and 99: 26. Kay L, Jorgensen T. Epidemiolog
- Page 100 and 101: 54. Hansen JM, Bytzer P, Schaffalit
- Page 102 and 103: 84. Breslin NP, Thomson AB, Bailey
- Page 104 and 105: 114. Ghosh S, Kinnear M. Dyspepsia
- Page 106 and 107: 142. Delaney BC, Wilson S, Roalfe A
- Page 108 and 109: 173. Soo S, Moayyedi P, Deeks J, De
- Page 112 and 113: 228. Fischbach LA, Goodman KJ, Feld
216. Sharma VK, Sahai AV, Cor<strong>de</strong>r FA, How<strong>de</strong>n CW. Helicobacter pylori eradicationis superior to ulcer healing with or without maintenance therapy to prevent furtherulcer haemorrhage. Aliment Pharmacol Ther 2001; 15: 1.939-1.947.217. Buring SM, Winner LH, Hatton RC, Doering PL. Dis<strong>con</strong>tinuation rates ofHelicobacter pylori treatment regimens: a meta-analysis. Pharmacotherapy 1999; 19:324-332.218. Penston JG, McColl KE. Eradication of Helicobacter pylori: an objectiveassessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-243.219. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation oftreatment regimens to cure Helicobacter pylori infection - a meta-analysis. AlimentPharmacol Ther 1999; 13: 857-864.220. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O´Morain Cet al. Eradication of Helicobacter pylori using one-week triple therapies combiningomeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1: 138-144.221. Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S et al. Impact ofrabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pyloriinfection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther1999; 13: 741-746.222. Wong BC, Wong WM, Yee YK, Hung WK, Yip AW, Szeto ML et al. Rabeprazolebased3- day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy forthe treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15:1.959-1.965.223. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M et al. Eradicationrates of clarithromycin-resistant Helicobacter pylori using either rabeprazole orlansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002; 16:1.933-1.938.224. Veldhuyzen Van Zanten S, Lauritsen K, Delchier JC, Labenz J, De Argila CM,Lind T et al. One-week triple therapy with esomeprazole provi<strong>de</strong>s effective eradicationof Helicobacter pylori in duo<strong>de</strong>nal ulcer disease. Aliment Pharmacol Ther 2000; 14:1.605-1.611.225. Tulassay Z, Kryszewski A, Dite P, Kleczkowski D, Rudzinski J, Bartuzi Z et al.One week of treatment with esomeprazole-based triple therapy eradicatesHelicobacter pylori and heals patients with duo<strong>de</strong>nal ulcer disease. Eur JGastroenterol Hepatol 2001; 13: 1.457-1.465.226. Laine L. Esomeprazole in the treatment of Helicobacter pylori. Aliment PharmacolTher 2002; 16 (Supl. 4): 115-118.227. Schmid CH, Whiting G, Cory D, Ross SD, Chalmers TC. Omeprazole plusantibiotics in the eradication of Helicobacter pylori infection: a meta-regressionanalysis of randomized, <strong>con</strong>trolled trials. Am J Ther 1999; 6: 25-36.102
Change language